KALA BIO Inc. (KALA) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

KALA BIO Inc.

NASDAQ: KALA · Real-Time Price · USD
16.01
0.74 (4.85%)
At close: Sep 11, 2025, 10:35 AM

Company Description

Kala Bio, Inc. is a biopharmaceutical company.

It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases.

The company was founded by Justin Hanes, Robert S.

Langer and Colin R.

Gardner in 2009 and is headquartered in Arlington, MA.

KALA BIO Inc.
KALA BIO Inc. logo
Country United States
IPO Date Jul 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 38
CEO Todd Bazemore

Contact Details

Address:
1167 Massachusetts Avenue
Arlington, Massachusetts
United States
Website https://www.kalarx.com

Stock Details

Ticker Symbol KALA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001479419
CUSIP Number 483119103
ISIN Number US4831192020
Employer ID 27-0604595
SIC Code 2834

Key Executives

Name Position
Todd Bazemore Interim Chief Executive Officer, President & Chief Operating Officer
Mary Reumuth CPA Chief Financial Officer, Treasurer & Secretary
Carl Rennie Executive Director of Account Management
Darius Kharabi J.D., M.B.A. Chief Business Officer
Dr. Francis S. Mah M.D. Chief Medical Advisor
Dr. Justin Hanes Ph.D. Founder & Chair of the Scientific Advisory Board
Dr. R. Kim Brazzell Ph.D. Head of R&D and Chief Medical Officer
Jill S. Steier Executive Director of Investor Relations & Corporate Communications
Josiah Craver Senior Vice President & Corporate Controller
Vincent Kosewski Senior Vice President of Manufacturing & Supply Chain Management

Latest SEC Filings

Date Type Title
Sep 02, 2025 4 Filing
Sep 02, 2025 8-K Current Report
Aug 08, 2025 10-Q Quarterly Report
Aug 08, 2025 8-K Current Report
Jul 09, 2025 8-K Current Report
Jun 26, 2025 4 Filing
Jun 26, 2025 4 Filing
Jun 26, 2025 4 Filing
Jun 26, 2025 4 Filing
Jun 26, 2025 4 Filing